COLUMBUS, Ohio--(BUSINESS WIRE)--DNA Nanobots, a biotechnology leader in DNA nanoparticles engineered for targeted therapeutics, announced today that Dr. John C. Byrd, M.D., has joined its scientific ...
Platform company uses antibody-targeted DNA nanoparticles to deliver a wide range of therapeutic payloads to desired tissue. “Most therapeutics fail in clinical trials,” said CEO and co-founder Jeff ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback